SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-024405
Filing Date
2024-05-20
Accepted
2024-05-20 17:26:51
Documents
14
Period of Report
2024-05-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20240517.htm   iXBRL 8-K 49686
  Complete submission text file 0001628280-24-024405.txt   222605

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20240517.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20240517_def.xml EX-101.DEF 16660
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20240517_lab.xml EX-101.LAB 28702
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20240517_pre.xml EX-101.PRE 17398
17 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20240517_htm.xml XML 4378
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 24965972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)